1. Home
  2. HSPO vs VRCA Comparison

HSPO vs VRCA Comparison

Compare HSPO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • VRCA
  • Stock Information
  • Founded
  • HSPO 2014
  • VRCA 2013
  • Country
  • HSPO United States
  • VRCA United States
  • Employees
  • HSPO N/A
  • VRCA N/A
  • Industry
  • HSPO Blank Checks
  • VRCA Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • VRCA Health Care
  • Exchange
  • HSPO Nasdaq
  • VRCA Nasdaq
  • Market Cap
  • HSPO 49.4M
  • VRCA 58.0M
  • IPO Year
  • HSPO 2022
  • VRCA 2018
  • Fundamental
  • Price
  • HSPO $11.99
  • VRCA $0.49
  • Analyst Decision
  • HSPO
  • VRCA Hold
  • Analyst Count
  • HSPO 0
  • VRCA 5
  • Target Price
  • HSPO N/A
  • VRCA $6.00
  • AVG Volume (30 Days)
  • HSPO 2.5K
  • VRCA 614.0K
  • Earning Date
  • HSPO 01-01-0001
  • VRCA 05-12-2025
  • Dividend Yield
  • HSPO N/A
  • VRCA N/A
  • EPS Growth
  • HSPO N/A
  • VRCA N/A
  • EPS
  • HSPO 0.27
  • VRCA N/A
  • Revenue
  • HSPO N/A
  • VRCA $7,566,000.00
  • Revenue This Year
  • HSPO N/A
  • VRCA $127.58
  • Revenue Next Year
  • HSPO N/A
  • VRCA $88.06
  • P/E Ratio
  • HSPO $45.10
  • VRCA N/A
  • Revenue Growth
  • HSPO N/A
  • VRCA 47.66
  • 52 Week Low
  • HSPO $10.87
  • VRCA $0.38
  • 52 Week High
  • HSPO $12.41
  • VRCA $11.41
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 59.93
  • VRCA 46.71
  • Support Level
  • HSPO $11.79
  • VRCA $0.38
  • Resistance Level
  • HSPO $12.11
  • VRCA $0.59
  • Average True Range (ATR)
  • HSPO 0.02
  • VRCA 0.09
  • MACD
  • HSPO -0.00
  • VRCA 0.01
  • Stochastic Oscillator
  • HSPO 65.67
  • VRCA 40.52

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Share on Social Networks: